Opinions
The Panic-Proof Portfolio (Stockchase Research)
Cullinan Oncology, Inc.
CGEM-Q
PAST TOP PICK
Oct 03, 2023
Stock price when the opinion was issued
You might be interested:
CGEM is a unique pharmaceutical company that collaborates with other developers and academia to develop drugs to help cancer patients. It has six on-going products in its pipeline. It trades below book value, at 6x earnings, and supports a 19% ROE. We like that it is low beta compared to the market. We recommend a stop-loss at $8.50, looking to achieve $17 — upside potential of 50%. Yield 0%
(Analysts’ price target is $28.75)We reiterate this biopharma company focused on oncology therapies, as a TOP PICK. Pilot projects are continuing to advance and they have a growing pipeline of new prospects. It trades under book value, supporting a 14% ROE. Cash reserves are growing, while debt is retired. We recommend maintaining the stop at $8.50, looking to achieve $17.00 -- upside of 36%. Yield 0%
(Analysts’ price target is $29.00)
Our PAST TOP PICK with CGEM has triggered its stop at $8.50. To remain disciplined, we recommend covering the position at this time. This will result in a net investment loss of 27%, when combined with previous recommendations.